Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:44:30 11/07/2025 BST			Pre-market 06:26:05
27.34 ^EUR	-1.58%		27.09	-0.90%

07-11	BAYER AG : Jefferies reiterates its Neutral rating	ZD
07-11	Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	RE

Bayer Recommends Third Indication For Bayer's Nubeqa For Patients With Advanced Prostate Cancer

Published on 20/06/2025 at 11:12

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bayer AG

BAYER AG : Jefferies reiterates its Neutral rating	07-11	ZD
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	07-11	RE
Bayer Receives U.K. Approval for Hot Flashes Treatment	07-10	DJ
Bayer receives approval for Lynkuet(TM) (Elinzanetant) in UK	07-10	RE
Bayer Rules Out Further Plant Closures in Germany After Frankfurt Exit	07-10	RE
Reaches socially acceptable agreements for the withdrawal from Frankfurt/Main site and secures remaining company sites in Germany until 2030	07-10	RE
Bayer Submits Gadoquatrane for EU Approval to Offer Lower-dose MRI Contrast Agent	07-10	MT
Bayer: application for approval of its contrast agent	07-10	CF
Bayer Seeks EU Approval for Low-Dose MRI Contrast Agent Gadoquatrane	07-10	MT
Bayer files for EU approval of gadoquatrane	07-10	RE
Bayer Wins Maiden Approval For Menopausal Hot Flashes Medication From UK Regulator	07-09	MT
German Equities Jump Amid EU-US Trade Deal Optimism	07-08	MT
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms caused by menopause	07-08	RE
UK Clears Bayer Medicine for Menopause-related Hot Flashes	07-08	MT
Bayer Treats First Patient in Early-stage Trial for Retinal Disorder Drug Candidate	07-08	MT
Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases	07-08	CI
Bayer: testing OpCT-001, an experimental cell therapy	07-08	CF
Vincerx Pharma, Inc. and Vnrx, Inc Announces Termination of License Agreement with Bayer Aktiengesellschaft and Bayer Intellectual Property Gmbh	07-07	CI
BAYER AG : JP Morgan gives a Neutral rating	07-07	ZD
BAYER AG : Goldman Sachs keeps its Buy rating	07-04	ZD
General Mills changing Nature Valley labels after lawsuit's herbicide claim	07-01	RE
Bayer Announces Executive Changes for North America	07-01	CI
BAYER AG : UBS reaffirms its Neutral rating	07-01	ZD
BAYER AG : JP Morgan reiterates its Neutral rating	06-30	ZD
European shares see monthly declines as markets eye trade developments	06-30	RE

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

90,885

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release

More about the company